Hoth Therapeutics (NASDAQ:HOTH) Receives Speculative Buy Rating from Benchmark

Benchmark reiterated their speculative buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $3.00 price objective on the stock.

Several other analysts have also issued reports on HOTH. HC Wainwright restated a buy rating and set a $4.00 target price on shares of Hoth Therapeutics in a research report on Friday, August 16th. EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a strong-buy rating in a research report on Wednesday, August 21st.

Hoth Therapeutics Price Performance

HOTH stock opened at $0.75 on Friday. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $1.73. The company has a market cap of $5.18 million, a P/E ratio of -0.47 and a beta of 0.84. The stock’s fifty day moving average price is $0.82 and its 200-day moving average price is $0.99.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Friday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.15. As a group, analysts expect that Hoth Therapeutics will post -1.18 earnings per share for the current year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.